Precision LBx Summit 2019

3rd Annual Precision LBx Summit is organized by Hanson Wade and will be held from Feb 19 - 20, 2019 at DoubleTree by Hilton Hotel San Diego - Mission Valley, San Diego, California, United States of America.

Conference Description:
Enhancing the Sensitivity, Reliability and Standardization of Liquid Biopsies to Advance Clinical Utility and Industry Applications for Improved Patient Treatment and Monitoring.

This Summit will bring together pharmaceutical, biotech, academic and clinical leaders to provide a platform to advance the validation, clinical utility and industry applications of liquid biopsies.

Showcasing robust data-lead studies and trials, the meeting will tackle challenges in technology, standardization and sensitivity of tests. Exploring a multitude of biomarkers from CTCs and ctDNA to RNA and exosomes, Precision LBx 2019 will advance the industry applications of liquid biopsies for oncology and chronic disease through CSF, urine and plasma-derived biomarkers.

As the dedicated scientific and networking forum of liquid biopsy trailblazers, the meeting is here to help precision medicine leaders radically improve the analysis and clinical utility of liquid biopsies as clinical monitoring tools.

Topics:
• Demonstrating reliability to advance the clinical utility of liquid biopsies
• Improving the clinical utility of a plethora of CSF, urine and plasma-derived biomarkers from cfDNA to exosomes
• Overcoming sensitivity and specificity challenges to progress the clinical applicability of liquid biopsy diagnostics
• Exploring liquid biopsy applications beyond oncology in various neurological indications
• Understanding the key developments required in improving clinician confidence in liquid biopsies as diagnostic tools

For pathologists, laboratories and oncologists at leading academic medical centers, Precision LBx 2019 will provide you insight from leading researchers and clinicians pioneering the development and standardization of liquid biopsy clinical testing, and the use of these assays to inform treatment decision making.

Time: 08:00 to 16:00

Speakers: Razelle Kurzrock (UCSD), Dennis Merkle (EMD Serono), Danielle Murphy (Pfizer), Joshua Xu (FDA), Stuart Martin (University of Maryland School of Medicine, Greenebaum Comprehensive Cancer Center)